Dystrophic Epidermolysis Bullosa Inversa – Case Report and Review of the Literature

Dystrophic epidermolysis bullosa inversa is a very rare subtype of inherited dystrophic epidermolysis bullosa with a unique clinical manifes- tation. Generalized blistering in the neonatal period and in early infancy im- proves with age, with lesions becoming restricted to intertriginous areas, axial parts of the trunk, and mucous membranes. In contrast to other variants of dystrophic epidermolysis bullosa, the inverse type has a more favorable prog- nosis. We present a case of a 45-year-old female patient with dystrophic epi- dermolysis bullosa inversa, diagnosed in adulthood based on typical clinical presentation, transmission electron microscopic findings, and genetic analy- sis. Additionally, genetic analysis revealed that the patient also suffered from Charcot-Marie-Tooth disease, a hereditary motor and sensory neuropathy. To our knowledge, the coexistence of these two genetic diseases has not been reported so far. We describe clinical and genetic findings in the patient and re- view previous reports on dystrophic epidermolysis bullosa inversa. A possible temperature-related pathophysiology for the peculiar clinical manifestation is discussed

Luskavica skozi prizmo prizadetosti srčno-žilnega sistema

Luskavica je kronična sistemska vnetna bolezen. Sistemsko vnetje pri luskavici vodi v številne pridružene bolezni, med katerimi so srčno-žilne bolezni glavni vzrok obolevnosti in umrljivosti. Ker zaenkrat presejanje na prisotnost dejavnikov tveganja za srčno-žilne bolezni in njihova obravnava pri bolnikih z luskavico še vedno ni zadostno, je ključno ozaveščanje tako zdravnikov, ki bolnike z luskavico zdravijo, kot tudi samih bolnikov z luskavico. Bolnike z luskavico namreč lahko že v zgodnji starosti pomembno ogrožajo srčno-žilni zapleti. S člankom želimo povzeti ključna spoznanja o tem in podati okvirne usmeritve za obravnavo dejavnikov tveganja za srčno-žilne bolezni pri bolnikih z luskavico

Killing Two Birds with One Stone: Potential Therapies Targeting Psoriasis and Atherosclerosis at the Same Time

Psoriasis is a chronic systemic inflammatory disease. Due to systemic inflammation, it is associated with many comorbidities. Among them, cardiovascular diseases represent the most common causes of morbidity and mortality in this population. Therefore, physicians treating patients with psoriasis should keep in mind that, as important as the treatment of psoriasis, awareness of cardiovascular risk deserves additional attention. Thus, in parallel with psoriasis treatment, a cardiovascular risk assessment must also be performed and addressed accordingly. In addition to encouraging non-pharmacologic strategies for a healthy lifestyle, physicians should be familiar with different pharmacologic options that can target psoriasis and reduce cardiovascular risk. In the present article, we present the pathophysiological mechanisms of the psoriasis and cardiometabolic interplay, our view on the interaction of psoriasis and cardiovascular disease, review the atherosclerotic effect of therapeutic options used in psoriasis, and vice versa, i.e., what the effect of medications used in the prevention of atherosclerosis could be on psoriasis